Gruppo Farmaimpresa

What Gruppo Farmaimpresa does

Gruppo Farmaimpresa is an Italian pharmaceutical contract development and manufacturing organization (CDMO) headquartered in Brescia, with production operations in Teverola, Caserta. Founded in 2007 and operating as a privately held Società a Responsabilità Limitata (S.R.L.) with 11–50 employees, the company develops, manufactures, and licenses medical devices (Class I, IIa, and III under EU MDR 2017/745), food supplements, and dermocosmetics. Its proprietary technology platform centers on formulation capabilities including advanced bioavailability, ingredient stability, controlled-release systems, and solubility enhancement, applied across pharmaceutical forms such as sprays, drops, ovules, syringes, topical gels, tablets, capsules, sachets, vials, creams, and emulsions.

The company operates a multi-revenue-stream B2B business model: (1) contract manufacturing / private label production for healthcare brands and pharmacies; (2) out licensing of more than 1,000 ready-to-commercialize formulations; (3) sale of finished products; (4) R&D services producing over 200 new formulations and 1,000 compliance verifications annually; (5) regulatory affairs and dossier development; and (6) clinical study support. It holds ISO 9001, ISO 13485, EU MDR 2017/745, and GDPR 679/2016 certifications. Customer segments span healthcare brands, international distributors, and, more recently, medical-aesthetic professionals via the 2025-launched Armonita sub-brand (Armonita Laboratories for aesthetic doctors; Armonita Skincare consumer lines Capri, Tokyo, Milano).

Go-to-market is event-driven and channel-partner oriented, with active participation in CPHI Worldwide (Frankfurt 2025), HNC Shanghai (2025), and World Health Exhibition WHX (Dubai 2026), supported by a trilingual website, scientific publication activity, and a B2B digital presence on LinkedIn and X. The company also sells to and sources from a defined ecosystem of specialized functions — Regulatory Affairs, Clinical Trials, Vigilance & Quality, Business Development, Logistics — reflecting an integrated one-stop-shop positioning rather than a pure-play contract manufacturer.

Name

Gruppo Farmaimpresa

Legal name

GFI - Gruppo Farmaimpresa srl

Website

https://farmaimpresa.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

Gruppo Farmaimpresa is an Italian pharmaceutical CDMO that develops, manufactures, and licenses medical devices, food supplements, and dermocosmetics for healthcare brands, pharmacies, distributors, and aesthetic-medicine professionals, with ISO and EU MDR certifications.

Ownership category

akta.pro rank

Headquarters

HQ city

Tavernola

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Contract Manufacturing (Private Label): Tailor-made production solutions for customers requiring manufacturing of medical devices, food supplements, and cosmetics under their own brand
2. Out Licensing: Licensing of over 1000 ready-to-commercialize products, plus adaptation of existing formulations to customer needs
3. Finished Products: Sale of finished products ready for immediate commercialization
4. Research and Development Services: Product development services including over 200 new formulations and 1000 compliance verifications per year, stability and efficacy testing
5. Regulatory Affairs: Support for product registration and market entry, including documentation and interface with regulatory authorities
6. Clinical Studies: Clinical trial data and efficacy studies to support product claims and regulatory compliance

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Gruppo Farmaimpresa is an Italian contract development and manufacturing organization (CDMO) that develops and produces medical devices (Class I, IIa, III), food supplements, and dermocosmetics for B2B clients. The company offers tailor-made private label manufacturing, out-licensing of over 1000 ready-to-market products, finished products for commercialization, and supporting R&D, regulatory affairs, dossier development, and clinical trial services.

Product overview

Gruppo Farmaimpresa is an Italian pharmaceutical contract manufacturer (CDMO) offering a comprehensive portfolio of medical devices, food supplements, and dermocosmetics. The company operates through three core product categories: Medical Devices (Class I, IIa, III) including sprays, drops, syringes, vaginal products, and topical formulations; Food Supplements in tablets, capsules, syrups, and sachets addressing cardiovascular, neurological, musculoskeletal, and metabolic health; and Dermocosmetics including creams, gels, and skincare lines. The company provides full-service contract manufacturing with Out Licensing of over 1000 ready-to-market products, supported by in-house R&D (200+ new formulations/year), Regulatory Affairs, Dossier Development, and Clinical Trials services. The recent Armonita sub-brand division offers professional aesthetic medicine products (Armonita Laboratories) and premium skincare collections (Capri, Tokyo, Milano) for the consumer market.

Differentiator

Problem solved

Functional benefit

Brands

• Armonita Laboratories: Professional line dedicated to aesthetic medicine doctors, featuring fillers, peels, and advanced treatments for natural and safe results
• Armonita Skincare

Products and services

• Contract Manufacturing (Produzione Conto Terzi) Third-party contract manufacturing of medical devices, food supplements, and dermocosmetics, providing tailor-made production solutions that meet specific client requirements under the client's brand. Certified under ISO 9001 and ISO 13485.
• Out Licensing Licensing of over 1000 ready-to-commercialize products to distributors and brands, with the ability to adapt existing formulations to client-specific needs and markets.
• Ricerca e Sviluppo (R&D)

Quantifiable outcome

• 200+ new formulations developed per year
• +2 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Hovione: Portuguese CDMO specializing in API synthesis, particle engineering, and drug product manufacturing. Comparable as a contract manufacturer with strong regulatory capabilities serving global pharmaceutical customers.
• Aenova Group: One of Europe's largest pharmaceutical CDMOs offering development and manufacturing across solid dosage forms, sterile liquids, and semi-solids. Comparable as a broad-based CDMO serving healthcare brands with regulatory and formulation services, though at significantly larger scale.
• CordenPharma: International CDMO providing contract development and manufacturing for APIs, drug products, and complex formulations including peptides and lipids. Comparable as a full-service pharmaceutical CDMO with regulatory expertise serving global healthcare customers.
• Recipharm AB: Swedish-headquartered global CDMO offering contract development and manufacturing for pharmaceuticals and biologics. Comparable as a contract manufacturer serving healthcare companies with regulatory and formulation expertise, but operating at much larger scale and broader pharma scope.
• Siegfried Holding AG: Swiss pharmaceutical CDMO offering API and finished drug product manufacturing. Comparable as a European-headquartered CDMO with full regulatory and development services serving global healthcare clients.
• PharmaZell: German CDMO focused on API manufacturing and related services. Comparable as a European CDMO serving healthcare customers with regulatory-compliant manufacturing capabilities.
• Catalent, Inc. Global pharma services leader offering contract development, manufacturing, and clinical supply across dosage forms and biologics. Comparable as a comprehensive pharmaceutical CDMO serving healthcare brands, though at vastly larger scale and broader scope.

Direct peers

• Labomar S.p.A. Italian CDMO specializing in food supplements, medical devices, and cosmetics with contract manufacturing, R&D, and regulatory services. Closest direct competitor given overlapping product categories (substance-based devices, supplements, dermocosmetics), private label model, and end-to-end service offering.
• Intercos S.p.A. Italian contract manufacturer specializing in cosmetic products, including skincare, makeup, and personal care for global beauty brands. Comparable as an Italian-headquartered contract manufacturer in the dermocosmetic space, serving brand customers through private label and licensing.
• Difass International: Italian nutraceutical and food supplement manufacturer with proprietary and private label products. Comparable as an Italian-headquartered player in the dietary supplement manufacturing space with overlapping therapeutic areas and B2B customer segments.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/gruppo-farmaimpresa

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gruppo Farmaimpresa